Industry News Archive

FDA Approves Nivolumab Plus Ipilimumab for Metastatic Colorectal Cancer

On July 11, the Food and Drug Administration (FDA) approved nivolumab (Opdivo, Bristol-Myers Squibb) plus Yervoy (ipilimumab, Bristol-Myers Squibb) for the treatment of adult and pediatric patients 12 years and older with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

Read the full Bristol-Myers Squibb press release here.

Posted 7/11/2018

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us